日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension

比美珠单抗治疗斑块状银屑病三年患者报告结局：BE RADIANT 随机临床试验及开放标签扩展研究

期刊:Jama Dermatology
影响因子:
doi:10.1001/jamadermatol.2025.6055
Augustin, Matthias; Feldman, Steven R; Warren, Richard B; Armstrong, April; Vender, Ronald; López-Ferrer, Anna; Dawe, William H; Lambert, Jérémy; Szilagyi, Balint; Hoepken, Bengt; Warham, Rhys; Gottlieb, Alice B
银屑病
发表日期：2026
文献求助 收藏

Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies

Bimekizumab 完全清除皮肤和指甲银屑病：III/IIIb 期研究中的疗效比较

期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-025-00968-2
Merola, Joseph F; Warren, Richard B; Thaçi, Diamant; Gordon, Kenneth B; Nishida, Emi; Strober, Bruce; Conrad, Curdin; Kavanagh, Sarah; López Pinto, José Manuel; Hoepken, Bengt; Gisondi, Paolo
银屑病
发表日期：2025
文献求助 收藏

Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector

单次注射320毫克比美珠单抗的方案：2毫升安全注射器和自动注射器

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-025-01366-6
Sebastian, Michael; Bagel, Jerry; Hoepken, Bengt; Knapp, Bertram; Bicer, Ceyhun; MacPherson, Merran; Langley, Richard G
发表日期：2025
文献求助 收藏

Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials

按亚组分析Bimekizumab治疗银屑病的疗效：3/3b期临床试验的事后分析

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-025-01557-1
Strober, Bruce; Boehncke, Wolf-Henning; Krueger, James G; Magnolo, Nina; Vender, Ronald; Warren, Richard B; López Pinto, José Manuel; Kavanagh, Sarah; Hoepken, Bengt; Gisondi, Paolo
银屑病
发表日期：2025
文献求助 收藏

Machine learning vs human experts: sacroiliitis analysis from the RAPID-axSpA and C-OPTIMISE phase 3 axSpA trials

机器学习与人类专家：来自 RAPID-axSpA 和 C-OPTIMISE 3 期 axSpA 试验的骶髂关节炎分析

期刊:Rheumatology Advances in Practice
影响因子:2.1
doi:10.1093/rap/rkae118
Proft, Fabian; Vahldiek, Janis L; Nicolaes, Joeri; Tham, Rachel; Hoepken, Bengt; Ufuktepe, Baran; Poddubnyy, Denis; Bressem, Keno K
关节炎
TIM
MIS
发表日期：2025
文献求助 收藏

Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status

根据基线 MRI 和 CRP 状态对非放射性中轴型脊柱关节炎患者接受 certolizumab pegol 治疗的长期临床结果进行分层

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2023-003884
Rudwaleit, Martin; Deodhar, Atul; Bauer, Lars; Gensler, Lianne; Hoepken, Bengt; Kumke, Thomas; Auteri, Simone Emanuele; Kim, Mindy; Maksymowych, Walter
关节炎
CRP
发表日期：2024
文献求助 收藏

Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis

比较已建立的和初步提出的ASAS MRI工作组关于放射学和非放射学中轴型脊柱关节炎骶髂关节炎症性MRI病变的临界值

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2023-003886
Baraliakos, Xenofon; Machado, Pedro M; Bauer, Lars; Hoepken, Bengt; Kim, Mindy; Kumke, Thomas; Tham, Rachel; Rudwaleit, Martin
炎症/感染
关节炎
炎症
发表日期：2024
文献求助 收藏

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study

塞妥珠单抗聚乙二醇治疗活动性非放射性中轴型脊柱关节炎患者的长期安全性和临床疗效：3期C-axSpAnd研究的3年结果

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2021-002138
van der Heijde, Désirée; Gensler, Lianne S; Maksymowych, Walter P; Landewé, Robert; Rudwaleit, Martin; Bauer, Lars; Kumke, Thomas; Kim, Mindy; Auteri, Simone Emanuele; Hoepken, Bengt; Deodhar, Atul
关节炎
发表日期：2022
文献求助 收藏

Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review

塞妥珠单抗治疗中轴型脊柱关节炎相关急性前葡萄膜炎患者的疗效：一项叙述性综述

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-022-00486-1
van der Horst-Bruinsma, Irene E; Robinson, Philip C; Favalli, Ennio G; Verbraak, Frank D; Kim, Mindy; Kumke, Thomas; Bauer, Lars; Hoepken, Bengt; Deodhar, Atul
关节炎
发表日期：2022
文献求助 收藏

Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study

根据基线 MRI 和 C 反应蛋白状态分层评估 Certolizumab Pegol 对非放射性中轴型脊柱关节炎患者的疗效：来自 C-axSpAnd 研究的分析

期刊:ACR Open Rheumatology
影响因子:2.8
doi:10.1002/acr2.11469
Robinson, Philip C; Maksymowych, Walter P; Gensler, Lianne S; Hall, Stephen; Rudwaleit, Martin; Hoepken, Bengt; Bauer, Lars; Kumke, Thomas; Kim, Mindy; de Peyrecave, Natasha; Deodhar, Atul
关节炎
发表日期：2022
文献求助 收藏